Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group
- PMID: 15169798
- DOI: 10.1200/JCO.2004.08.083
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group
Abstract
Purpose: A phase II clinical trial was conducted to evaluate the feasibility and tolerability of a prime/boost vaccine strategy using vaccinia virus and fowlpox virus expressing human prostate-specific antigen (PSA) in patients with biochemical progression after local therapy for prostate cancer. The induction of PSA-specific immunity was also evaluated.
Patients and methods: A randomized clinical trial was conducted by the Eastern Cooperative Oncology group and 64 eligible patients were randomly assigned to receive four vaccinations with fowlpox-PSA (rF-PSA), three rF-PSA vaccines followed by one vaccinia-PSA (rV-PSA) vaccine, or one rV-PSA vaccine followed by three rF-PSA vaccines. The major end point was PSA response at 6 months, and immune monitoring included measurements of anti-PSA and anti-vaccinia antibody titers and PSA-specific T-cell responses.
Results: The prime/boost schedule was well tolerated with few adverse events. Of the eligible patients, 45.3% of men remained free of PSA progression at 19.1 months and 78.1% demonstrated clinical progression-free survival. There was a trend favoring the treatment group that received a priming dose of rV-PSA. Although no significant increases in anti-PSA antibody titers were detected, 46% of patients demonstrated an increase in PSA-reactive T-cells.
Conclusion: Therapy with poxviruses expressing PSA and delivered in a prime/boost regimen was feasible and associated with minimal toxicity in the cooperative group setting. A significant proportion of men remained free of PSA and clinical progression after 19 months follow-up, and nearly half demonstrated an increase in PSA-specific T-cell responses. Phase III studies are needed to define the role of vaccination in men with prostate cancer or those who are at risk for the disease.
Similar articles
-
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.Clin Cancer Res. 2005 May 1;11(9):3353-62. doi: 10.1158/1078-0432.CCR-04-2062. Clin Cancer Res. 2005. PMID: 15867235 Clinical Trial.
-
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.Prostate. 2002 Oct 1;53(2):109-17. doi: 10.1002/pros.10130. Prostate. 2002. PMID: 12242725 Clinical Trial.
-
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.Clin Cancer Res. 2000 May;6(5):1632-8. Clin Cancer Res. 2000. PMID: 10815880 Clinical Trial.
-
CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.Adv Drug Deliv Rev. 2009 Mar 28;61(3):268-74. doi: 10.1016/j.addr.2008.12.005. Epub 2009 Jan 7. Adv Drug Deliv Rev. 2009. PMID: 19166887 Review.
-
Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center.Semin Oncol. 1999 Aug;26(4):448-54. Semin Oncol. 1999. PMID: 10482187 Review.
Cited by
-
Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer.Life (Basel). 2023 Jul 1;13(7):1498. doi: 10.3390/life13071498. Life (Basel). 2023. PMID: 37511873 Free PMC article. Review.
-
Vaccines as treatments for prostate cancer.Nat Rev Urol. 2023 Sep;20(9):544-559. doi: 10.1038/s41585-023-00739-w. Epub 2023 Mar 6. Nat Rev Urol. 2023. PMID: 36879114 Free PMC article. Review.
-
Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter.Int J Mol Sci. 2022 Oct 21;23(20):12647. doi: 10.3390/ijms232012647. Int J Mol Sci. 2022. PMID: 36293504 Free PMC article. Review.
-
Considering the potential for gene-based therapy in prostate cancer.Nat Rev Urol. 2021 Mar;18(3):170-184. doi: 10.1038/s41585-021-00431-x. Epub 2021 Feb 26. Nat Rev Urol. 2021. PMID: 33637962 Review.
-
Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer.Cancers (Basel). 2021 Jan 6;13(2):173. doi: 10.3390/cancers13020173. Cancers (Basel). 2021. PMID: 33419051 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous